ALEXION PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 288
- Registration Number
- NCT02145182
- Locations
- 🇧🇷
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02128269
- Locations
- 🇫🇷
Hopital Claude Huriez - CHU Lille, Lille, Nord, France
🇫🇷Hôpital Cochin, Paris, France 75679, France
🇯🇵Hokkaido University Hospital, Sapporo-shi, Hokkaido 060-8648, Japan
Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02112994
Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)
- Conditions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02104219
Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging
- Conditions
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02090179
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
- Conditions
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT02003144
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸The Research Center of Southern California, Oceanside, California, United States
🇺🇸Georgetown University Hospital, Washington, District of Columbia, United States
Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
- Conditions
- Interventions
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT01997229
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of California San Francisco-Fresno, Fresno, California, United States
🇺🇸University of California-Irvine, Orange, California, United States
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT01994382
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
- Conditions
- Interventions
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT01892345
- Locations
- 🇺🇸
John Hopkins University School of Medicine, Baltimore, Maryland, United States
🇦🇺University of Sydney, Brain and Mind Center, Camperdown, New South Wales, Australia
🇦🇺St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects
- First Posted Date
- 2013-06-21
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01883544
- Locations
- 🇺🇸
PAREXEL Baltimore EPCU, Baltimore, Maryland, United States